| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INXB | Common Stock | Award | +150K | 150K | 29 May 2024 | By the Forsyth Family Trust Dated July 20, 2001 | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INXB | Stock Option (right to buy) | Award | $0 | +30K | $0.00 | 30K | 30 May 2024 | Common Stock | 30K | $15.86 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. |
| F2 | The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. |
| F3 | This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. |
| F4 | This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. |